非布司他可用来治疗什么病症？

What conditions can it be used to treat? Febuxostat is a drug that can be used to treat hyperuricemia in gout patients and can be used for long-term treatment. Febuxostat controls the level of uric acid in gout patients by inhibiting the metabolism of purine into uric acid. From a clinical perspective, febuxostat has good efficacy and low side effects in treating hyperuricemia with gout symptoms.

Febuxostat is indicated for the treatment of chronic hyperuricemia (gout). 

Febuxostat was started at 10 mg/day for 2 weeks, then increased to 20 mg/day for 4 weeks, then to 40 mg/day. Starting with a low dose and gradually increasing the dose can prevent acute gout attacks caused by initial changes in blood uric acid levels. Treat with febuxostat 40 mg/day for 6 months, and check the uric acid level regularly. Generally, it takes 6 months to clean up excess blood uric acid in the body. 

After 6 months of treatment:

(1) If the blood uric acid level remains between 240 umol/l and 360 umol/l, maintain febuxostat 40 mg/day treatment.

  (2) If the blood uric acid level is higher than 360 umol/l, increase the dose of fexostatin by 60 mg/day, up to a maximum of 80 mg/day, and monitor blood uric acid, liver and kidney function regularly.

(3) If the blood uric acid level is lower than 240 umol/l, the dose of febuxostat can be reduced to 20 mg/day and the treatment can be maintained for 6 months.

Febuxostat is a new generation of xanthine oxidase inhibitor developed by Teijin Corporation of Japan. It is clinically used to treat hyperuricemia (gout). Its structure is completely different from the xanthine oxidase inhibitor drug developed 40 years ago. It is a new and highly efficient non-purine xanthine oxidase selective inhibitor. Xanthine oxidase is the key enzyme that promotes uric acid production.

Febuxostat can reduce uric acid levels in the blood of patients with hyperuricemic gout. Clinical studies have shown that febuxostat is safe and effective. Febuxostat is metabolized by the liver and does not rely on renal excretion. Therefore, there is no need to reduce the dose for patients with moderate to severe hepatic and renal insufficiency. In February 2009, the U.S. Food and Drug Administration approved it for the long-term treatment of patients with gout and hyperuricemia.